Skip to main content

Table 2 Metabolic parameters in 8-week-old mice (Based on Sugimoto et al. [15].)

From: Review: Miglitol has potential as a therapeutic drug against obesity

 

n

NC

NCM

HF

HFM

Body weight (g)

10–11

21.5 ± 0.2

22.2 ± 0.2

27.3 ± 0.4 *, **

25.8 ± 0.4 *, **, ***

HOMA-R

5

1.4 ± 0.3

1.1 ± 0.3

8.4 ± 1.3 *, **

4.0 ± 0.7 *, **, ***

Weight of epididymal white adipose tissue (g)

9–14

0.27 ± 0.02

0.28 ± 0.01

1.1 ± 0.08 *, **

0.85 ± 0.04 *, **, ***

Weight of subcutaneous white adipose tissue (g)

6

0.3 ± 0.03

Not measured

1.5 ± 0.15 *

0.98 ± 0.12 *, ***

Active glucose-dependent insulinotropic peptide (GIP) (pg/mL)

9–15

28.2 ± 3.6

20.4 ± 2.5

38.8 ± 4.7 **

32.0 ± 4.3

Active glucagon-like peptide 1 (GLP1) (pg/mL)

8–9

54.8 ± 7.9

61.1 ± 4.9

66 ± 7.5

76.9 ± 14.4

Concentration of miglitol (μmol/L)

3–4

Not measured

0.06 ± 0.02

Not Measured

0.26 ± 0.13

  1. * p < 0.05 vs NC; ** p < 0.05 vs NCM; *** p < 0.05 vs HF
  2. Values are means ± SE for 3–15 mice. Four-week-old male C57BL/6 J mice were divided into 4 groups: a control group (NC), which was fed normal chow; a normal chow plus miglitol (NCM) group, which was fed the normal chow plus miglitol; a high fat (HF) group, which was fed the high fat diet; and a high fat plus miglitol (HFM) group, which was fed the high fat diet plus miglitol. At 8 weeks the samples were collected under fasting conditions. Repeated-measures analysis of variance (ANOVA) with Tukey-Kramer post-hoc comparisons were performed for multiple comparisons